

Join Us for the Roche-Sponsored Virtual Symposium at EAHAD 2021 on Thursday, 4 February

Elevating Haemophilia A Care:

Where Are We Now and Where Are We Heading?

Thursday 4 February, 2021 (18.00-19.00 CET)

With the availability of novel therapies and the recently updated WFH guidelines, the bar is rising for treatment outcomes in people with haemophilia A (PwHA). By reviewing clinical and real-world data, this symposium will focus on the remaining unmet needs in PwHA and will discuss how novel therapies can confer patient benefits, beyond bleed protection.

The faculty will present two patient cases from their clinical experience and discuss what topics matter most to these individuals, other than bleed control, as the focus is moving towards quality of life, joint health, pain and treatment burden.

Come and join our renowned faculty for their perspectives on how haemophilia A care can be improved for all patients!



Add to Google calendar



Add to other calendars



EAHAD registration page

Agenda



Haemophilia A Treatment: A Snapshot Through Time Charles Percy

Navigating Haemophilia A Treatment Choices Cédric Hermans

Looking Beyond Bleeds: What Else is Important for PwHA? Gili Kenet

Putting the Patient Centre Stage: Clinical Experience with Novel Therapies in Haemophilia A All faculty

Live Q&A with the Audience All faculty

Looking Ahead to the Future of Treatment for PwHA Charles Percy

The expert panel includes:



Charles Percy
Queen Elizabeth Hospital
Birmingham
UK



Cédric Hermans
Cliniques Universitaires Saint-Luc
Université Catholique de Louvain
Belgium



Gili Kenet
Sheba Medical Center
Tel Aviv University
Israel

Don't forget to join the live Q&A session and interact with our expert panel on what matters to you!

You can register directly through the EAHAD website here.

Registration fees for the EAHAD 2021 virtual meeting have been considerably reduced, so do not miss out on this opportunity!







This is a non-promotional educational meeting sponsored by Hoffmann-La Roche. The meeting is intended for HCPs outside the USA and may include scientific information about investigational compounds that are not approved or valid in your jurisdiction.

M-XX-00003564 Date of preparation: December 2020